We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sanofi (SNY) Gets Label Expansion Nod for Sarclisa in Europe
Read MoreHide Full Article
Sanofi (SNY - Free Report) announced that the European Commission (EC) has granted approval to the label expansion of Sarclisa (isatuximab-irfc) for the treatment of adult patients with relapsed refractory multiple myeloma (RRMM) in the second- or later-line settings. The drug received the nod in combination with Amgen’s (AMGN) Kyprolis (carfilzomib) and dexamethasone (Kd) for treating adults with RRMM who have received at least one prior therapy.
The approval of Sarclisa plus Kd was based on data from phase III study — IKEMA — which showed that treatment with this combo regimen reduced risk of disease progression or death by 47% compared to Kd alone in MM patients.The FDA approved Sarclisa for a similar indication in March 2021
Please note that Sarclisa was approved in combination with Bristol Myers’ (BMY - Free Report) Pomalyst/Imnovid (pomalidomide) and dexamethasone for third- or later-line treatment of RRMM patients in Europe last year. With this label expansion, Sarclisa received two approvals in Europe within a year.
We note that both Kd and Pomalyst plus dexamethasone are standard-of-care regimens for RRMM patients.
Although the launch of the drug was hampered due to COVID-19 related restrictions, it generated nearly $50 million since its launch in any country.
Sanofi stock has gained 5.6% this year so far compared with an increase of 1.8% for the industry.
Launch of Sarclisa and Libtayo, a promising skin cancer drugs, boosted sales of the company’s Oncology segment in 2020. Libtayo, which is marketed in collaboration with Regeneron Pharmaceuticals (REGN - Free Report) , also received two label expansions from the FDA in February for skin cancer and lung cancer. The drug is also under review in Europe for similar indicatiojn. Label expansion of these two drugs is likely to bring additional oncology revenues in 2021.
Sanofi is developing Sarclisa as monotherapy or in combination with other drugs, including Roche’s (RHHBY - Free Report) Tecentriq as a potential treatment for solid tumors, leukemia or myeloma in several mid- to late-stage studies. Three late-stage studies are evaluating Libtayo in lung and skin cancer in different treatment settings, as well as cervical cancer.
In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?
Last year's 2020Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Image: Bigstock
Sanofi (SNY) Gets Label Expansion Nod for Sarclisa in Europe
Sanofi (SNY - Free Report) announced that the European Commission (EC) has granted approval to the label expansion of Sarclisa (isatuximab-irfc) for the treatment of adult patients with relapsed refractory multiple myeloma (RRMM) in the second- or later-line settings. The drug received the nod in combination with Amgen’s (AMGN) Kyprolis (carfilzomib) and dexamethasone (Kd) for treating adults with RRMM who have received at least one prior therapy.
The approval of Sarclisa plus Kd was based on data from phase III study — IKEMA — which showed that treatment with this combo regimen reduced risk of disease progression or death by 47% compared to Kd alone in MM patients.The FDA approved Sarclisa for a similar indication in March 2021
Please note that Sarclisa was approved in combination with Bristol Myers’ (BMY - Free Report) Pomalyst/Imnovid (pomalidomide) and dexamethasone for third- or later-line treatment of RRMM patients in Europe last year. With this label expansion, Sarclisa received two approvals in Europe within a year.
We note that both Kd and Pomalyst plus dexamethasone are standard-of-care regimens for RRMM patients.
Although the launch of the drug was hampered due to COVID-19 related restrictions, it generated nearly $50 million since its launch in any country.
Sanofi stock has gained 5.6% this year so far compared with an increase of 1.8% for the industry.
Launch of Sarclisa and Libtayo, a promising skin cancer drugs, boosted sales of the company’s Oncology segment in 2020. Libtayo, which is marketed in collaboration with Regeneron Pharmaceuticals (REGN - Free Report) , also received two label expansions from the FDA in February for skin cancer and lung cancer. The drug is also under review in Europe for similar indicatiojn. Label expansion of these two drugs is likely to bring additional oncology revenues in 2021.
Sanofi is developing Sarclisa as monotherapy or in combination with other drugs, including Roche’s (RHHBY - Free Report) Tecentriq as a potential treatment for solid tumors, leukemia or myeloma in several mid- to late-stage studies. Three late-stage studies are evaluating Libtayo in lung and skin cancer in different treatment settings, as well as cervical cancer.
Sanofi Price
Sanofi price | Sanofi Quote
Zacks Rank
Sanofi currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks Top 10 Stocks for 2021
In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?
Last year's 2020Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
AccessZacks Top 10 Stocks for 2021 today >>